Stockreport

Altimmune Signs Definitive Agreement to Acquire Spitfire Pharma, Inc. Adding NASH Drug Candidate to Portfolio

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH Greater impact on liver fat, infl [Read more]